Evidence map›Paper›PMID 26531309›Full record

ArticleArthritis research & therapy2015

Investigation of the cytokine response to NF-κB decoy oligonucleotide coated polysaccharide based nanoparticles in rheumatoid arthritis in vitro models.

Patricia R Wardwell, Martin B Forstner, Rebecca A Bader

Open access · goldAbstract read
In one paragraph

Article in Arthritis research & therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 32 citations in OpenAlex.

  1. Review
  2. Decoy oligonucleotides targeting NF-κB: a promising therapeutic approach for inflammatory diseases.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025
    Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Patricia R WardwellSyracuse Biomaterials Institute, Syracuse University, 318 Bowne Hall, Syracuse, NY, 13244, USA. prwardwe@syr.edu.
Martin B ForstnerSyracuse Biomaterials Institute, Syracuse University, 318 Bowne Hall, Syracuse, NY, 13244, USA.
Rebecca A BaderSyracuse Biomaterials Institute, Syracuse University, 318 Bowne Hall, Syracuse, NY, 13244, USA. babader@syr.edu.
Syracuse University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe transcription factor nuclear factor-kappa B (NF-κB) is highly involved in regulation of a number of cellular processes, including production of inflammatory mediators. Thus, this transcription factor plays a role in pathology of many diseases, including rheumatoid arthritis, an autoimmune disease hallmarked by an imbalance of pro and anti-inflammatory cytokines. Small nucleic acids with sequences that mimic the native binding site of NF-κB have been proposed as treatment options for RA; however due to low cellular penetration and a high degree of instability, clinical applications of these therapeutics have been limited.

methodsHere, we describe the use of N-trimethyl chitosan-polysialic acid (PSA-TMC) nanoparticles coated with decoy oligodeoxynucleotides (ODNs) specific to transcription factor NF-κB (PSA-TMC-ODN) as a method to enhance the stability of the nucleic acids and facilitate increased cellular penetration. In addition to decoy ODN, PSA-TMC nanoparticles were loaded with RA therapeutic methotrexate (MTX), to assess the anti-inflammatory efficacy of a combination therapy approach. Two different in vitro models, a cell line based model as well as a primary RA cell model were used to investigate anti-inflammatory activity. One way ANOVA followed by Holm-Sidak stepdown comparisons was used to determine statistical significance.

resultsIn general, free ODN did not significantly affect secretion of pro-inflammatory cytokines interleukin-6 (IL-6) and interleukin-8, (IL-8) while free MTX had variable efficacy. However, PSA-TMC-ODN and PSA-TMC-ODN-MTX resulted in significant decreases in the inflammatory mediators IL-6 and IL-8 in both cell models. In addition, PSA-TMC exhibited sufficient cellular uptake, as observed through fluorescence microscopy.

conclusionsThese results support our previous findings that PSA-TMC nanoparticles are an effective delivery vehicle for small nucleic acids, and effectively alter the pro-inflammatory state characteristic of RA.

Indexed as

Drug CarriersAntirheumatic AgentsArthritis, RheumatoidCell LineChitosanChromatography, High Pressure LiquidCytokinesEnzyme-Linked Immunosorbent AssayHumansIn Vitro TechniquesMethotrexateNanoparticlesOligodeoxyribonucleotidesOligonucleotidesPolysaccharidesSialic AcidsAntirheumatic AgentsChitosanCytokinesDrug CarriersMethotrexateNF-kappaB decoyN-trimethyl chitosan chlorideOligodeoxyribonucleotidesOligonucleotidesPolysaccharidespolysialic acidSialic Acids

Identifiers

PMID26531309
PMCPMC4632484
OpenAlexW1949695329

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.